SCGB1D2
Secretoglobin family 1D member 2
Also known as: LIPB, LPHB, SG1D2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O95969
- Gene
- SCGB1D2
- Ensembl
- ENSG00000124935
- Chromosome
- 11
- Canonical length
- 90 aa
- Protein class
- Cancer-related genes, Predicted secreted proteins
- Secretome location
- Secreted in other tissues
OverviewNCBI Gene
The protein encoded by this gene is a member of the lipophilin subfamily, part of the uteroglobin superfamily, and is an ortholog of prostatein, the major secretory glycoprotein of the rat ventral prostate gland. Lipophilin gene products are widely expressed in normal tissues, especially in endocrine-responsive organs. Assuming that human lipophilins are the functional counterparts of prostatein, they may be transcriptionally regulated by steroid hormones, with the ability to bind androgens, other steroids and possibly bind and concentrate estramustine, a chemotherapeutic agent widely used for prostate cancer. Although the gene has been reported to be on chromosome 10, this sequence appears to be from a cluster of genes on chromosome 11 that includes mammaglobin 2. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
90 residues, UniProt reviewed canonical sequence.
>O95969|SCGB1D2
1 MKLSVCLLLV TLALCCYQAN AEFCPALVSE LLDFFFISEP LFKLSLAKFD APPEAVAAKL
61 GVKRCTDQMS LQKRSLIAEV LVKILKKCSVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SCGB1D2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.42
- Highest tissue expression
- 3,767 nTPM
Expression across tissuesHPA
Tissue
- cervix: 3,767 nTPM
- breast: 1,149 nTPM
- skin: 368 nTPM
- epididymis: 336 nTPM
- fallopian tube: 103 nTPM
- choroid plexus: 96 nTPM
Single-cell type
- endometrial luminal cells: 4,583 nCPM
- endometrial glandular cells: 3,157 nCPM
- endometrial ciliated cells: 2,764 nCPM
- breast secretory cells: 892 nCPM
- fallopian tube ciliated cells: 739 nCPM
- endometrial stromal cells: 542 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 22 nTPM
- midbrain: 6.2 nTPM
- medulla oblongata: 4.6 nTPM
- white matter: 3.9 nTPM
- hypothalamus: 3.4 nTPM
- thalamus: 3.4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.27
- gnomAD pLI
- 0.27
- gnomAD missense Z
- -0.38
- DepMap mean gene effect
- 0
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SCGB1D2 as an antibody target. Whether an autoantibody or antibody against SCGB1D2 could matter depends on whether native SCGB1D2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SCGB1D2 is annotated as secreted, so native SCGB1D2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label SCGB1D2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...